FibroGen, Astellas commence Phase 3 trial of anemia therapeutic agent

FibroGen, Astellas commence Phase 3 trial of anemia therapeutic agent
FibroGen and Astellas Pharma have announced the commencement of Phase 3 trial of FG-4592/ASP1517 for treatment of anemia in chronic kidney disease (CKD) patients who are on dialysis and not on dialysis. The commencement triggered a $ 50m …

Full News here – Read more on Pharmaceutical Business Review

Leave a Reply